These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19156522)

  • 41. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
    Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
    Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era.
    Pozo-Laderas JC; Rodríguez-Perálvarez M; Muñoz-Villanueva MC; Rivera-Espinar F; Durban-García I; Muñoz-Trujillo J; Robles-Arista JC; Briceño-Delgado J
    Med Intensiva (Engl Ed); 2019; 43(5):261-269. PubMed ID: 29735173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?
    Sha M; Cao J; Xia Q
    J Hepatol; 2024 Apr; 80(4):e171-e172. PubMed ID: 37821020
    [No Abstract]   [Full Text] [Related]  

  • 46. Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP-Score.
    Menahem B; Duvoux C; Ganne N; Mallat A; Seror O; Calderaro J; Launoy G; Alves A; Cherqui D; Luciani A; Laurent A
    World J Surg; 2019 Jan; 43(1):221-229. PubMed ID: 30128773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.
    Merani S; Majno P; Kneteman NM; Berney T; Morel P; Mentha G; Toso C
    J Hepatol; 2011 Oct; 55(4):814-9. PubMed ID: 21334400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?".
    Norman JS; Mehta N
    J Hepatol; 2024 Apr; 80(4):e172-e173. PubMed ID: 38154740
    [No Abstract]   [Full Text] [Related]  

  • 49. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients.
    Komorowski AL; Hsu CC; Julka KD; Vasavada B; Lin CC; Wang CC; Chen CL
    Neoplasma; 2018 Mar; 65(3):455-460. PubMed ID: 29788730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
    Macdonald B; Sewell JL; Harper AM; Roberts JP; Yao FY
    Clin Transplant; 2015 Jun; 29(6):506-12. PubMed ID: 25777321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of HCC: the role of liver resection in the era of transplantation.
    De Carlis L; Giacomoni A; Pirotta V; Lauterio A; Slim AO; Bondinara GF; Cardillo M; Scalamogna M; Forti D
    Transplant Proc; 2001; 33(1-2):1453-6. PubMed ID: 11267370
    [No Abstract]   [Full Text] [Related]  

  • 57. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never.
    Hiatt JR; Carmody IC; Busuttil RW
    J Hepatol; 2005 Oct; 43(4):573-7. PubMed ID: 16112768
    [No Abstract]   [Full Text] [Related]  

  • 58. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course!
    Broelsch CE; Frilling A; Malago M
    J Hepatol; 2005 Oct; 43(4):569-73. PubMed ID: 16120470
    [No Abstract]   [Full Text] [Related]  

  • 59. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
    Berry K; Ioannou GN
    Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy.
    Farinati F; Giacomin A; Vanin V; Sergio A; Burra P; Cillo U; Di Nolfo A; Del Poggio P; Benvegnu L; Zoli M; Borzio F; Giannini EG; Caturelli E; Cazzagon N; Rapaccini GL; Trevisani F;
    Eur J Gastroenterol Hepatol; 2012 Feb; 24(2):195-202. PubMed ID: 22108511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.